TC-2216

DB06044InvestigationalSmall molecule

TC-2216 is an investigational novel small molecule that is being developed as an oral treatment for depression and anxiety disorders. TC-2216 showed greater potency than and anti-depressant effects comparable to... TC-2216 showed greater potency than and anti-depressant effects comparable to selective serotonin reuptake inhibitors and tricyclics, which are commonly used treatments for depression, as well as anxiety-relieving effects.

Mechanism: TC-2216 targets specific neuronal nicotinic receptors (NNRs), a class of receptors found in the central nervous system that play a critical role in regulating nervous system activity. TC-2216 selectively inhibits the alpha4beta2 NNR to modulate the release of neurotransmitters that are involved in mood regulation.
Curator reviewed
Primary indication: Investigated for use/treatment in anxiety disorders and depression.Curator reviewed
Formula / weight: C₁₂H₁₈ClN₃ · 239.75 g/mol (avg)
Also known as: 1,7-DIAZASPIRO(4.4)NONANE, 7-(3-PYRIDINYL)-, HYDROCHLORIDE (1:3) · TC-2216 TRIHYDROCHLORIDE
Code names: TC-2216

Resolves to

Compound

UNIIN6H5AE63T5CAS1159824-71-1

Structure

InChIKeyIKLDZHHQXNAQSS-UHFFFAOYSA-NSMILESCl.C1CNC2(C1)CCN(C2)C1=CN=CC=C1

Targets

P43681CHRNA4P17787CHRNB2

What you can answer from here — as of April 02, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

Which drugs share a target with TC-2216, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account